Fortified Oral Rehydration Therapy for Pediatric Diarrhea

NCT ID: NCT06137014

Last Updated: 2026-02-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-01

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to compare amino acid-fortified oral rehydration therapy (ORT) to the standard of care ORT in pediatric patients with acute gastroenteritis (AGE). The main questions it aims to answer are:

* can amino acid-fortified ORT reduce the duration and severity of AGE compared to standard of care ORT?
* can amino acid-fortified ORT increase the secretion of antimicrobial peptides in the gastrointestinal tract compared to standard of care ORT?

Participants will be assigned to the experimental treatment (amino acid-fortified ORT) or the standard of care ORT and their disease severity, duration, and stool antimicrobial peptide content.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Gastroenteritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amino acid-fortified oral rehydration therapy

Participants will consume the amino acid-fortified oral rehydration therapy (fORT) according to the World Health Organization (WHO) Treatment Plan A for ORT administration:

* Child under 24 months: 50 to 100 ml ORT after each loose stool (approximately 500 ml daily)
* Child from 2 to 10 years: 100 to 200 ml ORT after each loose stool (approximately 1000 ml daily)

Group Type EXPERIMENTAL

Fortified Oral Rehydration Therapy

Intervention Type DRUG

Oral rehydration solution with reduced glucose and added amino acids.

Standard of care oral rehydration therapy

Participants will consume the standard of care oral rehydration therapy according to the WHO Treatment Plan A for ORT administration:

* Child under 24 months: 50 to 100 ml after each loose stool (approximately 500 ml daily)
* Child from 2 to 10 years: 100 to 200 ml after each loose stool (approximately 1000 ml daily)

Group Type PLACEBO_COMPARATOR

Standard of Care Oral Rehydration Therapy

Intervention Type DIETARY_SUPPLEMENT

Glucose-based oral rehydration therapy according to World Health Organization guidelines.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fortified Oral Rehydration Therapy

Oral rehydration solution with reduced glucose and added amino acids.

Intervention Type DRUG

Standard of Care Oral Rehydration Therapy

Glucose-based oral rehydration therapy according to World Health Organization guidelines.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FORT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between the ages of 6 months and 5 years.
* Experiencing mild to moderate acute gastroenteritis for less than two (2) days before admission to Pediatric Emergency Department.
* Diarrhea presumed infectious

Exclusion Criteria

* Severe gastroenteritis with moderate to severe dehydration
* Requiring inpatient care
* Requiring antibiotics
* Requiring IV rehydration
* History of chronic diarrhea
* Presenting with diarrhea for greater than 2 days prior to admission
* Allergy to any of the ingredients in the study products
* Inborn metabolic disorder of amino acids
* Receives post-pyloric feedings
Minimum Eligible Age

6 Months

Maximum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Gerber Foundation

OTHER

Sponsor Role collaborator

Paul A Breslin

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Paul A Breslin

Professor of Nutritional Sciences

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Breslin, PhD

Role: PRINCIPAL_INVESTIGATOR

Rutgers, The State University of New Jersey

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Robert Wood Johnson University Hospital

New Brunswick, New Jersey, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Paul Breslin, PhD

Role: CONTACT

(848) 932-6085

Payton Harmon

Role: CONTACT

978-944-8484

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Paul AS Breslin, PhD

Role: primary

848-932-6080

Payton Harmon, BS

Role: backup

978-944-8484

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro2021002499

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.